Biohaven Pharmaceutical Holding Co. Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (24)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
Article By: ChinaBio® Today
Saturday, March 25, 2023 2:19 PM EDT
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product for $10 million upfront and $10 million in equity.
In this article: BHVN Also: SBMFF, TAK, CNTB
Read
Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains?
Article By: Zacks Investment Research
Friday, October 7, 2022 5:59 AM EDT
Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the 91.8% loss over the past four weeks.
In this article: BHVN Also: SGEN
Read
Healthcare Portfolio Performance - Small Stocks Perk Up!
Article By: Rod Raynovich
Saturday, November 14, 2020 2:43 PM EDT
Three weeks ago, we suggested that investors stay the course with healthcare and biotech because of potential volatility with the 2020 Election and COVID-19 cases spiking. We have seen a big shift toward energy, financial, and industrial stocks.
In this article: ABBV, ABT, MRK, NVAX, PACB, MRNA, NTLA, OCUL, BHVN, TWST, BNTX, CVAC Also: DNLI, IWM, XBI
Read
Biohaven Shares Should Not Be Down This Much On Study Miss, Says Piper Sandler
Article By: The Fly
Monday, February 10, 2020 10:03 AM EDT
Piper Sandler analyst Tyler Van Buren keeps an Overweight rating on Biohaven Pharmaceutical with a $100 price target.
In this article: BHVN
Read
The Week Ahead In Biotech: Pharma Earnings Pick Up Pace
Article By: Benzinga
Saturday, July 20, 2019 8:56 PM EDT
Biotech stocks had a relatively muted performance last week. Johnson & Johnson kickstarted the second-quarter reporting season for big pharma companies, beating forecasts and an upward adjustment to its full-year sales guidance.
In this article: BMY, DGX, EW, JNJ, MRK, ANIK, BIIB, CELG, BHVN
Read
All Posts

Latest Tweets for $BHVN

No tweets yet!

PARTNER HEADLINES